

Learn about common and serious Carisoprodol side effects, who's at higher risk, and when to contact your doctor. Practical tips for managing side effects safely.
Carisoprodol (brand name Soma) is a muscle relaxant prescribed for short-term relief of acute musculoskeletal pain. Like all medications, it comes with potential side effects — some mild and manageable, others serious enough to require immediate medical attention. This guide breaks down what to expect, who's at higher risk, and when to call your doctor.
Carisoprodol is a Schedule IV controlled substance that works by modifying nerve signals in the spinal cord and brain to reduce the sensation of pain and muscle spasm. It's typically prescribed for two to three weeks alongside rest and physical therapy. For a deeper look at how it works, see our guide on how Carisoprodol works.
Most people who take Carisoprodol experience at least one of these. They're usually mild and tend to improve as your body adjusts:
These side effects are the main reason the FDA recommends limiting Carisoprodol to short-term use. If any of them are severe or don't improve after a few days, let your doctor know.
While less common, these side effects require prompt medical attention. Call your doctor immediately or go to the ER if you experience:
Certain groups should use extra caution with Carisoprodol:
Carisoprodol is broken down in your liver by an enzyme called CYP2C19. Some people (called "poor metabolizers") process the drug much more slowly, leading to up to four times higher levels of Carisoprodol in their blood. If you're a poor metabolizer, you're more likely to experience pronounced drowsiness, dizziness, and other side effects. Your doctor may adjust your dose or choose a different medication.
Elderly patients are more sensitive to the sedating effects of Carisoprodol. The American Geriatrics Society's Beers Criteria lists Carisoprodol as potentially inappropriate for older adults due to the risk of falls, fractures, and excessive sedation.
Combining Carisoprodol with opioids, benzodiazepines, alcohol, or other sedating medications dramatically increases the risk of severe sedation and respiratory depression.
Carisoprodol is Pregnancy Category C — meaning animal studies have shown risk, but there aren't enough studies in humans. It's also excreted in breast milk at two to four times the concentration found in the mother's blood. Talk to your doctor before taking it if you're pregnant or nursing.
Carisoprodol is not recommended for patients under 16 years of age due to limited safety data.
Impaired liver or kidney function can affect how your body processes and eliminates Carisoprodol. Your doctor may need to adjust your dose or monitor you more closely.
If you're experiencing mild side effects, these strategies can help:
Contact your healthcare provider if you experience:
Go to the ER immediately for difficulty breathing, seizures, extreme drowsiness you can't be woken from, swelling of the face or throat, or temporary loss of vision or limb function.
Most people tolerate Carisoprodol well when it's used as directed — at the prescribed dose, for a short period, and without mixing it with alcohol or other sedating substances. The most common side effects like drowsiness and dizziness are usually manageable and improve over time.
The key is staying informed. Know what to watch for, take it exactly as prescribed, and don't hesitate to call your doctor if something doesn't feel right. If you're currently taking Carisoprodol and need help finding it at a pharmacy, Medfinder can help you locate availability near you.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.